Diabetic foot ulcers Market Forecast 2032 FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies ... - Barchart
| 4743 Stock | TWD 101.50 3.50 3.33% |
Slightly above 61% of Oneness Biotech's investor base is looking to short. The analysis of current outlook of investing in Oneness Biotech Co suggests that many traders are alarmed regarding Oneness Biotech's prospects. Oneness Biotech's investing sentiment can be driven by a variety of factors including economic data, Oneness Biotech's earnings reports, geopolitical events, and overall market trends.
Oneness Biotech stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Oneness daily returns and investor perception about the current price of Oneness Biotech Co as well as its diversification or hedging effects on your existing portfolios.
Oneness |
Diabetic foot ulcers Market Forecast 2032 FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies ... Barchart
Read at news.google.com
 |
Oneness Biotech Fundamental Analysis
We analyze Oneness Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oneness Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oneness Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Oneness Biotech is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Oneness Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oneness Biotech stock to make a market-neutral strategy. Peer analysis of Oneness Biotech could also be used in its relative valuation, which is a method of valuing Oneness Biotech by comparing valuation metrics with similar companies.
Peers
Oneness Biotech Related Equities
| 4174 | OBI Pharma | 0.32 |
| ||
| 4142 | Adimmune Corp | 0.47 |
| ||
| 6547 | Medigen Vaccine | 0.64 |
| ||
| 4162 | PharmaEngine | 1.81 |
| ||
| 4147 | TaiMed Biologics | 1.91 |
| ||
| 6541 | Tanvex BioPharma | 2.22 |
|
Additional Tools for Oneness Stock Analysis
When running Oneness Biotech's price analysis, check to measure Oneness Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oneness Biotech is operating at the current time. Most of Oneness Biotech's value examination focuses on studying past and present price action to predict the probability of Oneness Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oneness Biotech's price. Additionally, you may evaluate how the addition of Oneness Biotech to your portfolios can decrease your overall portfolio volatility.